Can we afford the cure? Exploring drug costs, access and outcomes

Описание: Rising prescription drug costs are creating difficult choices for patients, clinicians, employers, and health care systems. At the same time, breakthrough therapies and other health care innovations are expanding treatment possibilities — raising urgent questions about how to improve access while keeping care affordable and sustainable.

In this Permanente Live fireside chat, Stephen Parodi, MD, executive vice president at The Permanente Federation and The Permanente Medical Group, speaks with national health care leaders Peter J. Neumann, ScD, director of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, and Maisha Draves, MD, MPH, associate executive director of The Permanente Medical Group.

Watch the webinar or read the transcript for insights on:

Balancing access to life-changing medications with the need to manage rising costs
The growth of GLP-1 therapies, the promise of biosimilars, and the growing role of artificial intelligence
Evaluating value of pharmaceuticals through clinical outcomes, safety, patient experience, and total cost of care
Using deprescribing and coordinated care to improve outcomes and reduce unnecessary spending

00:00 – Introduction: Balancing Pharmacy Access & Affordability
03:07 – Defining Drug Value vs. Cost
05:40 – A Health System’s Perspective on Value & Safety
08:48 – GLP-1s: Efficacy, Scalability & System Impact
14:12 – Economic Considerations & Coverage for GLP-1s
19:08 – Off-Patent, Generic & Orphan Drug Pricing
22:11 – Biosimilars: Adoption Barriers & Opportunities
23:58 – The Role of PBMs & Supply Chain Transparency
26:33 – Deprescribing & Patient-Centered Medication Reviews
29:48 – Audience Q&A: Financing Multi-Million Dollar Therapies
37:15 – Audience Q&A: Artificial Intelligence in Prescribing & Care
40:33 – Integrated Health Systems & Formularies
44:05 – Key Takeaways & Closing Remarks